Bettoncelli G, Blasi F, Brusasco V, Centanni S, Corrado A, De Benedetto F, De Michele F, Di Maria G U, Donner C F, Falcone F, Mereu C, Nardini S, Pasqua F, Polverino M, Rossi A, Sanguinetti C M
.
Sarcoidosis Vasc Diffuse Lung Dis. 2014 May 12;31 Suppl 1:3-21.
COPD is a chronic pathological condition of the respiratory system characterized by persistent and partially reversible airflow obstruction, to which variably contribute remodeling of bronchi (chronic bronchitis), bronchioles (small airway disease) and lung parenchyma (pulmonary emphysema). COPD can cause important systemic effects and be associated with complications and comorbidities. The diagnosis of COPD is based on the presence of respiratory symptoms and/or a history of exposure to risk factors, and the demonstration of airflow obstruction by spirometry. GARD of WHO has defined COPD "a preventable and treatable disease". The integration among general practitioner, chest physician as well as other specialists, whenever required, assures the best management of the COPD person, when specific targets to be achieved are well defined in a diagnostic and therapeutic route, previously designed and shared with appropriateness. The first-line pharmacologic treatment of COPD is represented by inhaled long-acting bronchodilators. In symptomatic patients, with pre-bronchodilator FEV1 < 60%predicted and ≥ 2 exacerbations/year, ICS may be added to LABA. The use of fixed-dose, single-inhaler combination may improve the adherence to treatment. Long term oxygen therapy (LTOT) is indicated in stable patients, at rest while receiving the best possible treatment, and exhibiting a PaO2 ≤ 55 mmHg (SO2<88%) or PaO2 values between 56 and 59 mmHg (SO2 < 89%) associated with pulmonary arterial hypertension, cor pulmonale, or edema of the lower limbs or hematocrit > 55%. Respiratory rehabilitation is addressed to patients with chronic respiratory disease in all stages of severity who report symptoms and limitation of their daily activity. It must be integrated in an individual patient tailored treatment as it improves dyspnea, exercise performance, and quality of life. Acute exacerbation of COPD is a sudden worsening of usual symptoms in a person with COPD, over and beyond normal daily variability that requires treatment modification. The pharmacologic therapy can be applied at home and includes the administration of drugs used during the stable phase by increasing the dose or modifying the route, and adding, whenever required, drugs as antibiotics or systemic corticosteroids. In case of patients who because of COPD severity and/or of exacerbations do not respond promptly to treatment at home hospital admission should be considered. Patients with "severe or "very severe COPD who experience exacerbations should be carried out in respiratory unit, based on the severity of acute respiratory failure. An integrated system is required in the community in order to ensure adequate treatments also outside acute care hospital settings and rehabilitation centers. This article is being simultaneusly published in Multidisciplinary Respiratory Medicine 2014; 9:25.
慢性阻塞性肺疾病(COPD)是一种呼吸系统的慢性病理状态,其特征为持续性且部分可逆的气流受限,支气管(慢性支气管炎)、细支气管(小气道疾病)和肺实质(肺气肿)的重塑在其中起到不同程度的作用。COPD可导致重要的全身影响,并伴有并发症和合并症。COPD的诊断基于呼吸道症状的存在和/或危险因素暴露史,以及通过肺量计证实存在气流受限。世界卫生组织全球慢性阻塞性肺疾病防治创议(GARD)将COPD定义为“一种可预防和可治疗的疾病”。全科医生、胸科医生以及其他专科医生之间的协作,在必要时可确保对COPD患者进行最佳管理,前提是在预先设计并合理共享的诊断和治疗路径中明确了要实现的具体目标。COPD的一线药物治疗以吸入长效支气管扩张剂为代表。对于有症状且支气管扩张剂使用前第一秒用力呼气容积(FEV1)<60%预计值且每年≥2次加重的患者,可在长效β2受体激动剂(LABA)基础上加用吸入性糖皮质激素(ICS)。使用固定剂量的单一吸入器组合可能会提高治疗依从性。长期氧疗(LTOT)适用于病情稳定的患者,这些患者在接受最佳治疗的同时处于静息状态,且动脉血氧分压(PaO2)≤55 mmHg(血氧饱和度<88%)或PaO2在56至59 mmHg之间(血氧饱和度<89%),伴有肺动脉高压、肺心病、下肢水肿或血细胞比容>55%。呼吸康复适用于所有严重程度阶段、有症状且日常活动受限的慢性呼吸道疾病患者。它必须纳入针对个体患者的定制治疗中,因为它可改善呼吸困难、运动能力和生活质量。COPD急性加重是指COPD患者的日常症状突然恶化,超出正常的每日变化范围,需要调整治疗。药物治疗可在家中进行,包括增加稳定期使用药物的剂量或改变给药途径,并在必要时加用抗生素或全身用糖皮质激素等药物。对于因COPD严重程度和/或急性加重而在家中对治疗反应不迅速的患者,应考虑住院治疗。对于经历急性加重的“重度”或“极重度”COPD患者,应根据急性呼吸衰竭的严重程度在呼吸科病房进行治疗。社区需要一个综合系统,以确保在急性护理医院环境和康复中心之外也能提供充分的治疗。本文同时发表于《多学科呼吸医学》2014年;9:25。